Gadavist OverviewGadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and in the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations. Gadobutrol is marketed by Bayer AG as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist. Contents 1 Medical uses 2 Adverse effects 3 Use in specif...
Read more Gadavist Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Gadobutrol
Recent Gadavist Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 1mmol/ml
- Solution: 1.20944gm/2ml (604.72mg/ml), 18.1416gm/30ml (604.72mg/ml), 39.3068gm/65ml (604.72mg/ml), 4.5354gm/7.5ml (604.72mg/ml), 6.0472gm/10ml (604.72mg/ml), 9.0708gm/15ml (604.72mg/ml)
NDC Database Records for Gadavist: (1 result)Sorted by National Drug Code
- 50419-325 Gadavist 604.72 mg/ml Intravenous Injection by Bayer Healthcare Pharmaceuticals Inc.